AU Patent

AU2005237254B2 — Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor

Assigned to Novartis AG · Expires 2010-02-04 · 16y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: AU2005237254B2
Jurisdiction: AU
Classification: —
Expires: 2010-02-04
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.